知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.023 秒)

    Treatment of bladder cancer to overcome chemoresistance
    1.
    发明授权
    Treatment of bladder cancer to overcome chemoresistance 有权

    公开(公告)号：US10011877B2

    公开(公告)日：2018-07-03

    申请号：US14846189

    申请日：2015-09-04

    申请人： Genedia Biotech Co., Ltd.

    发明人： Jingde Zhu

    IPC分类号： C12Q1/6886

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/154 ,  C12Q2600/158

    摘要： The disclosure demonstrates the correlation of the methylation status of the miR-193a gene and the expression level of the miR-193a-3p transcript with the resistance of bladder cancer cells to certain chemotherapeutic drugs including pirarubicin (Pi), pacilitaxol (Pa), adriamycin (Ad), epirubicin hydrochloride (EH), and cispaltin (Ci), but not others (e.g, hydroxycamptothecin (Hy), gemcitabine (Ge) and mitomycin (Mi)). Further, the disclosure identifies seven target genes (SRSF2, PLAU, HIC2, LOXL4, HOXC9, PSEN1, and ING5) that are directly regulated by miR-193a-3p. The methylation/expression status of miR-193a-3p alone or in combination of the expression level of the target genes can serve as valuable indicators for chemotherapy outcome of a bladder cancer patient with a corresponding chemotherapeutic drug, and can be drug targets for sensitizing a bladder cancer patient for that drug.

    TREATMENT OF BLADDER CANCER TO OVERCOME CHEMORESISTANCE
    2.
    发明申请
    TREATMENT OF BLADDER CANCER TO OVERCOME CHEMORESISTANCE 有权
    治疗乳腺癌来实现化疗

    公开(公告)号：US20170067113A1

    公开(公告)日：2017-03-09

    申请号：US14846189

    申请日：2015-09-04

    申请人： Genedia Biotech Co., Ltd.

    发明人： Jingde Zhu

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/154 ,  C12Q2600/158

    摘要： The disclosure demonstrates the correlation of the methylation status of the miR-193a gene and the expression level of the miR-193a-3p transcript with the resistance of bladder cancer cells to certain chemotherapeutic drugs including pirarubicin (Pi), pacilitaxol (Pa), adriamycin (Ad), epirubicin hydrochloride (EH), and cispaltin (Ci), but not others (e.g, hydroxycamptothecin (Hy), gemcitabine (Ge) and mitomycin (Mi)). Further, the disclosure identifies seven target genes (SRSF2, PLAU, HIC2, LOXL4, HOXC9, PSEN1, and ING5) that are directly regulated by miR-193a-3p. The methylation/expression status of miR-193a-3p alone or in combination of the expression level of the target genes can serve as valuable indicators for chemotherapy outcome of a bladder cancer patient with a corresponding chemotherapeutic drug, and can be drug targets for sensitizing a bladder cancer patient for that drug.

    摘要翻译： 本发明揭示了miR-193a基因的甲基化状态与miR-193a-3p转录物的表达水平与膀胱癌细胞对某些化疗药物的抗性的相关性，包括吡柔比星（Pi），pacilitaxol（Pa），阿霉素 （Ad），盐酸表柔比星（EH）和cispaltin（Ci），而不是其他（例如羟基喜树碱（Hy），吉西他滨（Ge）和丝裂霉素（Mi））。 此外，该公开内容鉴定了由miR-193a-3p直接调节的七个靶基因（SRSF2，PLAU，HIC2，LOXL4，HOXC9，PSEN1和ING5）。 miR-193a-3p单独或组合靶基因表达水平的甲基化/表达状态可作为具有相应化学治疗药物的膀胱癌患者的化疗结果的有价值的指标，并且可以作为敏化一种 该药物的膀胱癌患者。

    MIR-193A-3P and associated genes predict tumorigenesis and chemotherapy outcomes
    3.
    发明授权
    MIR-193A-3P and associated genes predict tumorigenesis and chemotherapy outcomes 有权
    MIR-193A-3P和相关基因预测肿瘤发生和化疗结果

    公开(公告)号：US09540698B2

    公开(公告)日：2017-01-10

    申请号：US14807647

    申请日：2015-07-23

    申请人： Genedia Biotech Co., Ltd.

    发明人： Jingde Zhu

    IPC分类号： G01N33/574 ,  C12Q1/68

    CPC分类号： C12Q1/6886 ,  A61K31/513 ,  C12Q2600/106 ,  C12Q2600/154 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/57484 ,  G01N2800/52 ,  G01N2800/54

    摘要： The disclosure provides a correlation between the expression level of the miR-193a gene, which can be regulated by its methylation status, and both tumorigenesis of and the resistance of a cancer cell to a pyrimidine antimetabolite (5-FU) based chemotherapy. In addition to the methylation status and the expression of miR-193a, its downstream genes, such as E2F1, SRSF2, and apoptotic genes such as caspase 2, are also involved and can serve as useful markers for cancer therapy prognosis and for therapy selection.

    摘要翻译： 本公开提供了可以通过其甲基化状态调节的miR-193a基因的表达水平与癌细胞的肿瘤发生和抗细胞对基于嘧啶抗代谢药（5-FU）的化学疗法的抗性之间的相关性。 除了甲基化状态和miR-193a的表达外，其下游基因如E2F1，SRSF2和凋亡基因如半胱天冬酶2也有作用，可作为癌症治疗预后和治疗选择的有用标志物。